Medtronic Q4 FY26 Report: The PFA Growth Story Meets Its First Real Test

What happened

Medtronic reports Q4 results today with consensus expecting $9.61B revenue and $1.55 EPS, but the real focus is pulsed-field ablation (PFA) momentum after the Abbott Volt launch. The analyst revisions ahead of the print reflect mixed opinions as the market weighs the company's 4-point share gain against intensifying competition. The recently acquired SPR Therapeutics bolsters the neuromodulation portfolio but is immaterial to near-term results. The $382M adverse jury verdict in the Applied litigation, subject to automatic trebling and injunction risk, remains an unmodeled overhang. Today's call must confirm that PFA growth, pricing, and share gains are holding steady—or the stock's 26.6x P/E offers little forgiveness.

Implication

At $95.60 with P/E 26.6 and EV/EBITDA 16.2, the stock already prices a sustained cardiovascular re-acceleration. The next 3–6 months hinge on proof that PFA share gains persist despite Abbott Volt's commercialization, while the market absorbs a $382M jury verdict that will treble automatically—a cash-flow event the company has not yet reserved. If Q4 results reaffirm +80% ablation growth and show no pricing compression, the base case ($102) remains intact; any deceleration or pricing language would validate the bear scenario ($80). The Applied litigation timeline (post-trial motions, appeal, possible injunction) adds binary legal risk that is asymmetric to the downside. For new capital, an attractive entry is $90; current levels offer poor risk/reward until FY26 Q4 clarity and mid-2026 Investor Day targets are set.

Thesis delta

The thesis has not changed; we still need to wait for Q4 data. The key update is that today's report is the primary near-term catalyst to validate PFA durability and pricing. No shift until we see whether management sustains 'share gain' language and addresses Abbott Volt head-on.